During titration , incidences of treatment-emergent adverse events ( TEAEs ) were @ % ( @/@ ) with tapentadol PR and @ % ( @/@ ) with morphine CR ; incidences of nausea , vomiting , and dry mouth were lower with tapentadol PR than with morphine CR .